Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 3, 2014, Pages 324-331

  Negishi, Kazuaki ^a   Negishi, Tomoko ^a   Haluska, Brian A ^b   Hare, James L ^b   Plana, Juan Carlos ^a   Marwick, Thomas H ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

anthracyclines; beta blocker; cardiotoxicity; strain; trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; METOPROLOL; MITOXANTRONE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOBAL LONGITUDINAL STRAIN; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITRAL VALVE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTHRACYCLINES; BETA-BLOCKER; CARDIOTOXICITY; STRAIN; TRASTUZUMAB;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOTONIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84896692295     PISSN: 20472404     EISSN: None     Source Type: Journal    
DOI: 10.1093/ehjci/jet159     Document Type: Article

References (32)

1. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-96.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al. Cancer treatment and survivorship statistics, 2012. CA-Cancer J Clin 2012;62:220-41.
3. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-9.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
7. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ,Wasserman TH et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-45.
8. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77-84.
9. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301.
10. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-7.
11. Fallah-Rad N,Walker JR,Wassef A, Lytwyn M, Bohonis S, Fang T et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.
12. Jessup M, AbrahamWT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. 2009 ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
13. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.
14. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-Analysis. Eur J Cancer 2013;49:2900-9.
15. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-6.
16. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493-8.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
18. Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997;18:507-13.
19. Leitman M, Lysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M et al. Twodimensional strain-A novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr 2004;17:1021-9.
20. Bansal M,ChoGY, Chan J, Leano R, Haluska BA, Marwick TH. Feasibilityand accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr 2008;21: 1318-25.
21. Maxwell SE, Delaney HD. Designing Experiments and Analyzing Data: A Model Comparison Perspective. Belmont,Wadsworth; 2003.
22. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
23. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 2011;108:619-28.
24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365: 1273-83.
25. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011; 107:1375-80.
26. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010; 160:487 e1-7.
27. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48: 2258-62.
28. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185:218-27.
29. Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011;11:318.
30. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, RosjoH et al. Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology 2012;123:240-7.
31. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-Analysis of published randomized trials. BMC Cancer 2007;7:153.
32. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr 2011;12:167-205.